What the Obsidian Therapeutics and Galera Therapeutics merger means for OBX-115
Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.
Pharma & Biotech
Pharma & Biotech
Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply
Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.
Pharma & Biotech
Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.
Pharma & Biotech
Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?
Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.
Pharma & Biotech
Imneskibart enters the ASCO spotlight as Aulos Bioscience tests a smarter IL-2 strategy in melanoma
Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.